Tyme Technologies (Tyme Technologies) Quick Ratio : 14.06 (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Tyme Technologies's quick ratio for the quarter that ended in Jun. 2022 was 14.06.

Tyme Technologies has a quick ratio of 14.06. It generally indicates good short-term financial strength.

The historical rank and industry rank for Tyme Technologies's Quick Ratio or its related term are showing as below:

TYME' s Quick Ratio Range Over the Past 10 Years
Min: 1.17 Med: 4.5 Max: 31
Current: 14.06

During the past 11 years, Tyme Technologies's highest Quick Ratio was 31.00. The lowest was 1.17. And the median was 4.50.

TYME's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.485 vs TYME: 14.06

Tyme Technologies Quick Ratio Historical Data

The historical data trend for Tyme Technologies's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies Quick Ratio Chart

Tyme Technologies Annual Data

Trend

Nov12

Nov13

Nov14

Dec15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Quick Ratio

Get a 7-Day Free Trial

6.54

2.60

5.03

19.43

10.68

Tyme Technologies Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Quick Ratio	Get a 7-Day Free Trial															16.12	16.21	14.04	10.68	14.06

Competitive Comparison of Tyme Technologies's Quick Ratio

For the Biotechnology subindustry, Tyme Technologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyme Technologies's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyme Technologies's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Tyme Technologies's Quick Ratio falls into.

Tyme Technologies Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Tyme Technologies's Quick Ratio for the fiscal year that ended in Mar. 2022 is calculated as

Quick Ratio (A: Mar. 2022 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(78.896	-	0)	/	7.386
	=	10.68

Tyme Technologies's Quick Ratio for the quarter that ended in Jun. 2022 is calculated as

Quick Ratio (Q: Jun. 2022 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(79.02	-	0)	/	5.621
	=	14.06

Tyme Technologies (NAS:TYME) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Tyme Technologies Quick Ratio Related Terms

Thank you for viewing the detailed overview of Tyme Technologies's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyme Technologies (Tyme Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921

Website

https://www.tymeinc.com

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Executives

Michael Demurjian	director, 10 percent owner, officer: Chief Operating Officer	157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman	director, 10 percent owner, officer: CEO and Chief Science Officer	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl	director	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido	officer: Chief Financial Officer	C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini	officer: Corporate Controller	17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry	director	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M	officer: Acting Chief Medical Officer	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman	officer: EVP, Product Development	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor	officer: President and CFO	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin	officer: Chief Operating Officer	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105